MX9304765A - Vacuna de adenovirus recombinante. - Google Patents

Vacuna de adenovirus recombinante.

Info

Publication number
MX9304765A
MX9304765A MX9304765A MX9304765A MX9304765A MX 9304765 A MX9304765 A MX 9304765A MX 9304765 A MX9304765 A MX 9304765A MX 9304765 A MX9304765 A MX 9304765A MX 9304765 A MX9304765 A MX 9304765A
Authority
MX
Mexico
Prior art keywords
recombinant adenovirus
warm
mediated immunity
adenovirus vaccine
blooded mammal
Prior art date
Application number
MX9304765A
Other languages
English (en)
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur
Shankaranarayana Murthy
Shaw-Guang Lin Lee
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of MX9304765A publication Critical patent/MX9304765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención proporciona un método para producir anticuerpos o inmunidadmediada por células para un organismo infeccioso en un mamífero de sangrecaliente, el cual comprende administra al mamífero de sangre caliente,adenovirus recombinantes vivos intranasal, intramuscular osubcutáneamente, en los cuales la proteína estructuras del virión está sincambio de aquella del adenovirus nativo a partir del cual se produce eladenovirus recombinante, y el cual contiene el gen que codifica para elantígeno que corresponde a los anticuerpos o para inducir la inmunidadmediada por células.
MX9304765A 1992-08-07 1993-08-05 Vacuna de adenovirus recombinante. MX9304765A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92649192A 1992-08-07 1992-08-07

Publications (1)

Publication Number Publication Date
MX9304765A true MX9304765A (es) 1995-01-31

Family

ID=25453282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304765A MX9304765A (es) 1992-08-07 1993-08-05 Vacuna de adenovirus recombinante.

Country Status (18)

Country Link
EP (1) EP0586076B1 (es)
JP (1) JP4093597B2 (es)
KR (1) KR100347219B1 (es)
AT (1) ATE243755T1 (es)
AU (2) AU680826B2 (es)
BR (1) BR9303226A (es)
CA (1) CA2101463C (es)
DE (1) DE69333057T2 (es)
DK (1) DK0586076T3 (es)
ES (1) ES2201055T3 (es)
FI (1) FI114318B (es)
HK (1) HK1009978A1 (es)
HU (2) HU214364B (es)
IL (1) IL106508A (es)
MX (1) MX9304765A (es)
NZ (1) NZ248328A (es)
PT (1) PT586076E (es)
ZA (1) ZA935355B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG43029A1 (en) * 1993-08-11 1997-10-17 American Home Prod Recombinant adenovirus vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
EP0800403A2 (en) * 1994-12-30 1997-10-15 Chiron Corporation Non-traumatic administration of gene delivery vehicles
KR100464395B1 (ko) * 1997-10-13 2005-02-28 삼성전자주식회사 반도체소자의비아홀형성방법
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
WO2009026471A1 (en) 2007-08-21 2009-02-26 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
EP2769703B1 (en) 2009-04-30 2022-04-06 Zeltiq Aesthetics, Inc. Device for removing heat from subcutaneous lipid-rich cells
CA2787374A1 (en) 2010-01-25 2011-07-28 Zeltiq Aesthetics, Inc. Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
WO2012103242A1 (en) 2011-01-25 2012-08-02 Zeltiq Aesthetics, Inc. Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
WO1992011028A1 (en) * 1990-12-19 1992-07-09 Epitope, Inc. Hiv reverse transcriptase vaccine
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes

Also Published As

Publication number Publication date
HU211691A9 (en) 1995-12-28
ES2201055T3 (es) 2004-03-16
AU4446593A (en) 1994-02-10
IL106508A (en) 1998-02-22
AU3422797A (en) 1997-11-20
FI933495A0 (fi) 1993-08-06
ATE243755T1 (de) 2003-07-15
KR100347219B1 (ko) 2003-02-25
HUT67302A (en) 1995-03-28
JP4093597B2 (ja) 2008-06-04
DE69333057D1 (de) 2003-07-31
FI933495A (fi) 1994-02-08
KR940003566A (ko) 1994-03-12
DK0586076T3 (da) 2003-10-20
IL106508A0 (en) 1993-11-15
AU715190B2 (en) 2000-01-20
EP0586076A2 (en) 1994-03-09
DE69333057T2 (de) 2004-07-08
EP0586076B1 (en) 2003-06-25
PT586076E (pt) 2003-11-28
ZA935355B (en) 1995-01-23
BR9303226A (pt) 1994-03-08
JPH06165689A (ja) 1994-06-14
HK1009978A1 (en) 1999-06-11
NZ248328A (en) 1997-05-26
HU214364B (hu) 1998-03-30
CA2101463A1 (en) 1994-02-08
AU680826B2 (en) 1997-08-14
HU9302285D0 (en) 1993-11-29
CA2101463C (en) 2007-03-13
FI114318B (fi) 2004-09-30
EP0586076A3 (en) 1994-04-20

Similar Documents

Publication Publication Date Title
MX9304765A (es) Vacuna de adenovirus recombinante.
EA200100425A1 (ru) Новые способы терапевтической вакцинации
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
DK1033995T3 (da) Hele eller sprængte insektceller som adjuvans for antigener
DK1618889T3 (da) Influenzavaccine
DE69112634D1 (de) Immunogene komplexe, insbesondere iscoms.
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
PE97298A1 (es) Composicion para vacunas
DK0638316T3 (da) Rekombinante adenovirusvacciner
ES2039239T3 (es) Vacuna contra el virus varicela-zoster.
AR036793A1 (es) Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
GB9818133D0 (en) Vaccine
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
ATE116860T1 (de) Pseudorabiesvirus-impfstoff.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: MANUFACTURE FRANCAISE DES PNEUMATIQUES MICHELIN

MM Annulment or lapse due to non-payment of fees